MGTA

Magenta Therapeutics (MGTA)

Magenta Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MGTA

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/17	05:10	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/09/17	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/09/13	09:45	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/08/09	05:26	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/08/09	05:21	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/08/09	05:10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/08/09	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/06/06	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	09:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	09:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	09:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	09:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	08:59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	08:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	08:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	06:24	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/29	06:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/10	05:27	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/10	05:20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/05/10	05:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/04/12	05:10	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/04/12	05:09	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/04/12	05:05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/04/02	07:34	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/04/02	07:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/03/28	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/03/22	06:10	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/03/22	06:02	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/03/22	05:07	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:MGTA	Magenta Therapeutics Inc
2024/03/22	05:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MGTA	Magenta Therapeutics Inc